# Peripheral tolerance

Source: https://onco.cc/terms/peripheral-tolerance/  
OnCo record `peripheral-tolerance` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Peripheral tolerance is the set of controls that restrain mature immune cells after they have developed, which helps stop them reacting against the body's own tissues. Tumours can use the same controls to avoid attack, and a treatment that releases them can also harm healthy organs.

## Summary

Central tolerance acts during lymphocyte development, in T-cell selection in the thymus and B-cell development in bone marrow. Peripheral tolerance acts on mature cells in tissues and lymphoid organs. The two names say when and where restraint operates, not that they are two complete filters that remove every self-reactive receptor. For T cells, tolerance mechanisms that operate in the thymus before the cells mature and circulate are called central tolerance, but not every self-antigen is made in the thymus, so central tolerance alone is insufficient and additional mechanisms restrain mature circulating T cells (Xing and Hogquist, 2012). For B cells, tolerance regulated at the immature B-cell stage in the bone marrow is called central tolerance and works through clonal deletion and receptor editing, while mechanisms that act after B cells leave the bone marrow were described as not fail-safe and mostly reversible (Nemazee, 2017). Several mechanisms contribute: anergy (reduced responsiveness), deletion (removal by cell death), suppression by regulatory T cells, inhibitory pathways and limited supporting signals. Deletion and restraint differ, because a deleted clone is gone and a restrained clone may remain and respond differently under defined conditions. In transgenic mice, cross-presentation of a self-antigen led to deletion of autoreactive CD8 T cells, and adding CD4 helper cells impaired that deletion and caused diabetes in 68 per cent of mice, whereas the CD8 cells alone did not (Kurts et al., 1997). In mice, transferring CD4 cells depleted of CD25-positive cells into athymic recipients caused multiple autoimmune diseases, and giving back CD4-positive CD25-positive cells within a limited period prevented them in a dose-dependent way (Sakaguchi et al., 1995). A separate mechanism acts on ligand supply: CTLA-4 captured CD80 and CD86 from opposing cells by trans-endocytosis, impairing costimulation through CD28 (Qureshi et al., 2011).

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- A quiet response has other explanations. Immune ignorance is a setting where the relevant cells have not effectively met the antigen, which is different from tolerance after an encounter, and an antibody concentration alone cannot show that self-reactive B cells were deleted or restrained. In a mouse model with a self antigen in the pancreatic islets, a low antigen concentration left CD8 T cells ignorant of it, while a higher concentration allowed cross-presentation and peripheral deletion (Kurts et al., 1999). Tolerance is inferred from mechanism-specific experiments and not from a blood score: a controlled response to a defined antigen, lineage and count evidence for deletion, and coculture or pathway tests for suppression, with cell type, prior exposure and comparator stated. A non-response can also reflect absent receptors, poor viability or an unsuitable assay.
- For cancer, many tumour-associated targets are also found in healthy tissue, and normal tolerance helps explain why recognition and activation are not interchangeable. Tumours can exploit regulatory pathways, but a treatment that releases a restraint can also harm normal organs. A neoantigen may differ from the normal molecule, yet a sequence difference alone does not show that it is recognised, that useful activation follows or that it is safe; candidate specificity, natural display and cross-reactivity with healthy tissue are separate tests. A self-similarity calculation screens candidates and does not measure central or peripheral tolerance in a person. Reviews of human tumour antigens note that differentiation antigens are expressed by some tumours and the matching healthy tissue, that responses to melanoma differentiation antigens occur in patients and healthy donors (suggesting central tolerance to them is incomplete), and that the autoimmune side effects of checkpoint blockade likely reflect breakage of peripheral tolerance to antigens of normal tissues (Vigneron, 2015).

## Sources

- CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity.: https://doi.org/10.1084/jem.186.12.2057
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.: https://doi.org/10.4049/jimmunol.155.3.1151
- Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.: https://doi.org/10.1126/science.1202947
- T-cell tolerance: central and peripheral.: https://doi.org/10.1101/cshperspect.a006957
- Mechanisms of central tolerance for B cells.: https://doi.org/10.1038/nri.2017.19
- CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose.: https://doi.org/10.1073/pnas.96.22.12703
- Human Tumor Antigens and Cancer Immunotherapy.: https://doi.org/10.1155/2015/948501

## Connected records

- targets: [CD28](https://onco.cc/targets/cd28/), [CD80 (B7-1)](https://onco.cc/targets/cd80/), [CD86 (B7-2)](https://onco.cc/targets/cd86/), [CTLA-4](https://onco.cc/targets/ctla4/), [FOXP3](https://onco.cc/targets/foxp3/)
- terms: [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/), [Immune system](https://onco.cc/terms/immune-system/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [T cell](https://onco.cc/terms/t-cell/)

---
JSON: https://onco.cc/api/v1/entities/peripheral-tolerance.json